Alnylam Pharmaceuticals Inc

• Alnylam shares surged due to positive clinical data and favorable Wall Street analyst commentary. • Amvuttra demonstrated superior efficacy and strong clinical trial results for treating cardiomyopathy. • The company reports $3.71B in annual revenue and neutral technical indicators.

• Renewed talc litigation uncertainty exerts downward pressure on Johnson and Johnson's share price. • Increased competition and rising input costs challenge the MedTech division's operating margins. • Analysts lowered price targets amid regulatory concerns and pharmaceutical patent expiration risks.

• Eli Lilly shares declined due to profit-taking and increased competitive pressures in weight-loss markets. • Regulatory concerns regarding Medicare price negotiations are impacting institutional sentiment toward large-cap pharmaceutical stocks. • Technical factors, including broken moving averages and portfolio rebalancing, contributed to the intraday volatility.

• AstraZeneca shares fell after the Wainua drug failed a late-stage clinical trial. • The CARDIO-TTRansform trial did not meet its primary cardiovascular mortality reduction objectives. • High usage of competitor medication likely masked the drug's therapeutic efficacy in patients.